TY  - GEN
AU  - Visani,Giuseppe
AU  - Malerba,Lara
AU  - Stefani,Pietro Maria
AU  - Capria,Saveria
AU  - Galieni,Piero
AU  - Gaudio,Francesco
AU  - Specchia,Giorgina
AU  - Meloni,Giovanna
AU  - Gherlinzoni,Filippo
AU  - Giardini,Claudio
AU  - Falcioni,Sadia
AU  - Cuberli,Francesca
AU  - Gobbi,Marco
AU  - Sarina,Barbara
AU  - Santoro,Armando
AU  - Ferrara,Felicetto
AU  - Rocchi,Marco
AU  - Ocio,Enrique M
AU  - Caballero,Maria Dolores
AU  - Isidori,Alessandro
TI  - BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients
SN  - 1528-0020
PY  - 2011///1121
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Bendamustine Hydrochloride
KW  - Cytarabine
KW  - Drug Resistance, Neoplasm
KW  - Etoposide
KW  - Female
KW  - Follow-Up Studies
KW  - Graft Survival
KW  - Hematopoietic Stem Cell Transplantation
KW  - Hodgkin Disease
KW  - immunology
KW  - Humans
KW  - Lymphoma, Non-Hodgkin
KW  - Male
KW  - Melphalan
KW  - Middle Aged
KW  - Nitrogen Mustard Compounds
KW  - Recurrence
KW  - Remission Induction
KW  - Salvage Therapy
KW  - methods
KW  - Transplantation Conditioning
KW  - Transplantation, Autologous
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1182/blood-2011-04-351924
ER  -